Related Experiment Video
Updated: May 22, 2026
09:52
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
Published on: April 19, 2013
Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis
Chen-Yu Wang1, Donald S Stapleton, Kathryn L Schueler
1Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Journal of Lipid Research
|May 26, 2012
Summary
Nonalcoholic fatty liver disease (NAFLD) is linked to obesity and diabetes. Researchers identified the Tsc2 gene on chromosome 17 as a key factor influencing NAFLD development in mice, impacting liver fat metabolism.
Area of Science:
- Genetics and Molecular Biology
- Metabolic Diseases
- Hepatology
Background:
- Nonalcoholic fatty liver disease (NAFLD) is a prevalent liver condition often co-occurring with metabolic disorders like obesity and insulin resistance.
- Genetic factors play a significant role in the susceptibility and progression of NAFLD.
- Understanding the genetic underpinnings of NAFLD is crucial for developing targeted therapies.
Purpose of the Study:
- To identify the specific gene responsible for a quantitative trait locus (QTL) associated with NAFLD on chromosome 17.
- To investigate the role of the identified gene, Tuberous Sclerosis 2 (Tsc2), in the development of fatty liver disease.
- To elucidate the molecular mechanisms by which Tsc2 influences lipogenesis and liver cell proliferation.
Main Methods:
- Crossbreeding of C57BL/6 (B6) and BTBR mouse strains, both carrying the Lep(ob/ob) mutation for genetic obesity.
- Quantitative trait locus (QTL) mapping to pinpoint the chromosomal region associated with NAFLD.
- Analysis of Tsc2 gene function, including its role as an inhibitor of mammalian target of rapamycin (mTOR).
- Assessment of lipogenic gene expression and de novo lipogenesis in liver cells (AML12) and pancreatic beta cells (Ins1) from Tsc2(+/-) mice.
Main Results:
- A significant NAFLD QTL was mapped to chromosome 17, with Tsc2 identified as the underlying gene.
- Tsc2(+/-) mice exhibited increased hepatic lipogenic gene expression in an insulin-dependent manner.
- A coding single nucleotide polymorphism in Tsc2 between B6 and BTBR strains altered its ability to inhibit lipogenic gene expression and de novo lipogenesis.
- This polymorphism affected Tsc2 binding affinity to Tsc1, impacting Tsc2 stability and downstream signaling.
Conclusions:
- Tsc2 is a critical gene influencing NAFLD susceptibility and progression.
- Genetic variations in Tsc2 can modulate hepatic lipogenesis and contribute to fatty liver disease development.
- The interaction between Tsc2, Tsc1, and the mTOR pathway represents a potential therapeutic target for NAFLD.
Related Concept Videos
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19X-linked Traits
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
01:19X-linked Traits
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.